USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ADENOSINE THERAPEUTICS, LLC
City: CHARLOTTESVILLE
State: VA
Zip+4: 22902
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,579,257.00 9
SBIR Phase II $4,908,100.00 5
STTR Phase I $2,432,035.00 11
STTR Phase II $2,191,130.00 2

Award List:

N/A

Award Year / Program / Phase: 2000 / STTR / Phase I
Agency: HHS
Research Institution: University of Virginia
Principal Investigator: Ian Sarembock, Principal Investigator
Award Amount: $100,000.00
RI Contact: N/A

N/A

Award Year / Program / Phase: 2000 / STTR / Phase I
Agency: HHS
Research Institution: University of Virginia
Principal Investigator:
Award Amount: $100,000.00
RI Contact: N/A

N/A

Award Year / Program / Phase: 2000 / STTR / Phase I
Agency: HHS
Research Institution: University of Virginia
Principal Investigator:
Award Amount: $100,000.00
RI Contact: N/A

Antagonists of A2B Receptors Improve Insulin Sensitivity

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert A. Figler
Award Amount: $100,000.00
Abstract:
DESCRIPTION (Scanned from the Applicant's Abstract): Blockade of A2B adenosine receptors (A2BARs) increases insulin sensitivity in insulin resistant obese Zucker rats by an effect on skeletal muscle. We have synthesized and characterized the first potent and selective… More

ANTAGONIST OF A2B ADENOSINE RECEPTORS FOR ASTHMA

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert A. Figler
Award Amount: $100,000.00
Abstract:
DESCRIPTION: (Adapted from the Investigator's Abstract): Adenosine administered as an aerosol to asthmatics causes bronchoconstriction, while in non-asthmatics adenosine causes bronchodilation. This occurs because the activation of A2B adenosine receptors on sensitized mast cells… More

NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ray A. Olsson
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): The development of new treatments for the effective reduction of renal injury associated with acute renal failure and kidney transplantation will have a great impact on health care delivery to patients with renal disease. Acute ischemic renal failure affects 5… More

NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ray A. Olsson
Award Amount: $818,282.00
Abstract:
DESCRIPTION (provided by applicant): The development of new treatments for the effective reduction of renal injury associated with acute renal failure and kidney transplantation will have a great impact on health care delivery to patients with renal disease. Acute ischemic renal failure affects 5… More

A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF VIRGINIA
Principal Investigator: W. M. Scheld
Award Amount: $198,360.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has… More

A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF VIRGINIA
Principal Investigator: Robert D. Thompson
Award Amount: $0.00
RI Contact: N/A
Abstract:
epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR)… More

A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert D. Thompson
Award Amount: $137,289.00
Abstract:
DESCRIPTION (provided by applicant): The central goal of this research is to develop a new drug to prevent spinal cord reperfusion injury secondary to aortic clamping that occurs frequently during thoracic surgery. Irreversible spinal cord injury resulting in paraplegia or… More

A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Robert D. Thompson
Award Amount: $928,760.00
Abstract:
DESCRIPTION (provided by applicant): The central goal of this research is to develop a new drug to prevent spinal cord reperfusion injury secondary to aortic clamping that occurs frequently during thoracic surgery. Irreversible spinal cord injury resulting in paraplegia or… More

A2a Adenosine Receptors and Equine Sepsis

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: USDA
Principal Investigator: Robert Thompson
Award Amount: $75,000.00
Abstract:
NON-TECHNICAL SUMMARY: This is a phase I SBIR proposal by Adenosine Therapeutics for 6 months of support to synthesize and evaluate novel compounds as agonists of equine A2A adenosine receptors. Some of these compounds have been found to be very effective in reducing rodent mortality form endotoxin… More

Long Acting Agonists of Adenosine A2a Receptors

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert D. Thompson
Award Amount: $100,885.00
Abstract:
DESCRIPTION (provided by applicant): Adenosine is an endogenous nucleoside that exerts its physiological effects through four G-protein coupled receptors A1, A2A, A2B, and A3. Adenosine Therapeutics, LLC is interested in the anti-inflammatory actions mediated by the A2A receptor subtype. A lead… More

Novel A2A Adenosine Agonists in Vascular Protection

Award Year / Program / Phase: 2004 / STTR / Phase II
Agency: HHS
Research Institution: N/A
Principal Investigator: Jayson M. Rieger
Award Amount: $1,247,577.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setagon, Inc., and the University of Virginia. The work described here will be done at Adenosine… More

Antagonists of A2B Receptors Improve Insulin Sensitivity

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Robert A. Figler
Award Amount: $1,424,445.00
Abstract:
DESCRIPTION (provided by applicant): This is a phase II SBIR grant to develop a new therapy for the treatment of type II diabetes. Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation of selective antagonists… More

A2A Adenosine Receptor Agonist for the Treatment of IBD

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert D. Thompson
Award Amount: $673,023.00
Abstract:
DESCRIPTION (provided by applicant): Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation and use of a family of potent and highly selective agonists of A2A adenosine receptors. One of these compounds, ATL146e,… More

A2a Adenosine Agonist Cardiac Reperfusion Injury

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Shannon P. Williams
Award Amount: $288,277.00
Abstract:
DESCRIPTION (provided by applicant): Founded in 1999, Adenosine Therapeutics LLC (ATL) is a drug discovery and development company that has developed a family of potent and selective adenosine A2A receptor agonists. With the help of STTR funding, ATL has developed a lead adenosine A2A receptor… More

A2a Adenosine Blockers for Parkinson's Disease

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: BOSTON UNIVERSITY SCHOOL OF MEDICINE
Principal Investigator: Robert D. Thompson
Award Amount: $139,176.00
RI Contact: N/A
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. However, the initial clinical trial was stopped in phase 3 due to detection of animal toxicity… More

Antagonists of A2B Adenosine Receptors for Asthma

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Robert D. Thompson
Award Amount: $1,440,613.00
Abstract:
DESCRIPTION (provided by applicant): This is a Phase II SBIR proposal to develop a new therapy for the treatment of asthma. The desired outcome will be the identification of a therapeutic candidate to replace theophylline, a non-selective adenosine receptor antagonist that is effective in treating… More

A2A Adenosine Receptors and Equine Sepsis

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: USDA
Principal Investigator: Robert Thompson
Award Amount: $296,000.00
Abstract:
Endotoxemia (Sepsis) affects horses of all breeds and ages and is the leading causes of death in adult horses and foals. Consequently, its economic impact on the equine industry in the United States is devastating. This project seeks to develop new treatments for this disease.

A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF VIRGINIA
Principal Investigator: Jayson M. Rieger
Award Amount: $132,798.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of… More

Adenosine A2A receptor antagonists for the treatment of cocaine addiction

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jayson M. Rieger
Award Amount: $104,783.00
Abstract:
DESCRIPTION (provided by applicant): Selective antagonists of A2A adenosine receptors (A2AR) are thought to have potential for the treatment of addictive disorders, including cocaine addiction. This proposal is a phase I STTR to investigate proprietary nov el, potent, selective and bioavailable A2AR… More